Adalimumab-induced lupus erythematosus
- 1 July 2008
- journal article
- case report
- Published by SAGE Publications in Lupus
- Vol. 17 (7), 676-678
- https://doi.org/10.1177/0961203307088291
Abstract
Adalimumab, an anti-tumour necrosis factor agent, especially used in the treatment of rheumatoid arthritis, has a good safety profile. One of the most common side-effects of adalimumab is the development of autoantibodies. Despite the induction of autoantibodies, the clinical presentation of immune-mediated complications upon adalimumab therapy, including a lupus-like syndrome, is very rare. We have recently evaluated a new case of adalimumab-induced lupus erythematosus.This publication has 8 references indexed in Scilit:
- Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody levelRheumatology, 2006
- Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trialAnnals Of The Rheumatic Diseases, 2006
- Musculoskeletal manifestations and autoimmune diseases related to new biologic agentsCurrent Opinion in Rheumatology, 2006
- Adalimumab: a review of side effectsExpert Opinion on Drug Safety, 2005
- Lupus erythematosus with leflunomide: induction or reactivation?Annals Of The Rheumatic Diseases, 2005
- Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus.Lupus, 2004
- Subacute cutaneous lupus erythematosus associated with leflunomideClinical and Experimental Dermatology, 2004
- Benefyts of lefiunomide in systemic lupus erythematosus: a pilot observational studyLupus, 2001